NCT00694291View on ClinicalTrials.gov

Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

June 30, 2008

Primary Completion Date

June 30, 2010

Conditions

Prostate Cancer

Interventions

DRUG

Sorafenib

400 mg orally twice daily

DRUG

Placebo

Matching Placebo

Trial Locations (1)

19111

Fox Chase Cancer Center, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

Fox Chase Cancer Center

OTHER